ImmunoGen impresses

ImmunoGen Inc. (Nasdaq: IMGN) impressed with sharply higher second quarter revenue and earnings of 16 cents per share compared with 4 cents per share a year earlier that surpassed analyst expectations by a wide margin. Shares of the biotechnology company climbed $1.43 to close at $7.63.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.